Open company graph database — free web & API
Login

Qualips Corporation

クオリプス株式会社
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
51
Related companies
10
§01

Basic information

BASIC
Head office
8F Nakanoshima Qross, 4-3 Nakanoshima, Kita-ku, Osaka, Osaka Prefecture, Japan
Chief executive
Takayuki Kusanagi
Capital
1,667,000,000 JPY (16 100 millionJPY)
Employees (non-consolidated)
56 people
Employees (consolidated)
51 people
Start date
2017-03-21
End date
§02

Websites

1 DOMAINS
§03

Business

4
Regenerative medicine-related businessManufacture and sale of human iPS cell-derived cardiac muscle cell sheetsResearch and development of medical technologiesJoint research through industry-academia collaboration
§04

Related companies

10 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
iReheart Inc.
Group Customer
Cuorips Inc.
Group
Qualips Healthcare Science Co., Ltd.
Group
スタンフォード大学
Group
Osaka University
Group
新潟大学大学院医歯学総合研究科
Group
Asahi Intecc Co., Ltd.
Group
株式会社セルキューブ
Group
DAIICHI SANKYO COMPANY, LIMITED
Group
順天堂大学医学部附属順天堂医院
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

34 EVENTS

Cuore Corporation (now Qualips Corporation): Established in Yokohama, Kanagawa PrefectureSources

Date of establishment: March 21, 2017Sources

The established CellCube Inc. founded Cuore Inc. in Nishi Ward, Yokohama City, Kanagawa Prefecture, to commercialize human iPS cell-derived cardiac muscle cell sheetsSources

Succeeded in business transfer from Cellcube Corporation and inherited the joint research course "Advanced Regenerative Medicine Joint Research Course" in industry-academia collaboration with Osaka UniversitySources

Changed company name to Qualips CorporationSources

Received business transfer of human iPS cell-derived cardiac muscle cell sheets from CellCube Inc., and succeeded to the joint research course "Advanced Regenerative Medicine Joint Research Course" with Osaka University (ended at the end of September 2025)Sources

Concluded share subscription agreement with Daiichi Sankyo Co., Ltd.Sources

Changed trade name from Cuore Inc. to Quolips Inc.Sources

Concluded joint research and development agreement with Daiichi Sankyo Co., Ltd.Sources

Established Quolips Healthcare Science Inc. as a consolidated subsidiary in Chuo Ward, TokyoSources

Established iReheart Inc. as a consolidated subsidiary in the United StatesSources

Concluded a joint research agreement with Stanford University Heart and Thoracic Surgery in the United StatesSources

Established research facility (joint research course) at Osaka University, Suita CampusSources

Applied for clinical research plan on ischemic heart disease using human iPS cell-derived cardiac muscle cell sheets at Osaka UniversitySources

Relocated headquarters to Chuo-ku, TokyoSources

Conducted third-party allotment of shares to Daiichi Sankyo Co., Ltd., Kyoto University Innovation Capital Co., Ltd., and othersSources

Osaka University submitted clinical trial notification for physician-led clinical trial on ischemic heart disease using human iPS cell-derived cardiac muscle cell sheets: supporting the physician-led clinical trial (independent administrative agency Pharmaceuticals and Medical Devices Agency (PMDA))Sources

Start of the physician-led clinical trial (cohort A) (first transplantation)Sources

Started construction of a commercial cell culture processing facility (commonly known as "CLiC-1") with a research facility in Minoo City, Osaka PrefectureSources

Completion of the physician-led clinical trial (cohort A) (third transplantation)Sources

Conducted third-party allotment of shares to Daiseki Pharmaceutical Co., Ltd., Kyoto University Innovation Capital Co., Ltd., Terumo Corporation, Daidan Corporation, Stem Cell Research Institute, Asahi Intecc Co., Ltd. (headquartered in Seto, Aichi Prefecture), and othersSources

JIC Venture Growth Investments Co., Ltd. operated JIC Venture Growth Fund No. 1 Investment Limited Partnership, JAFCO Group Co., Ltd. managed JAFCO SV6 Investment Limited Partnership, JAFCO SV6-S Investment Limited Partnership, Kyoto Venture NCC No. 2 Investment Limited Partnership managed by Japan Venture Capital Co., Ltd., Osaka Venture NCC No. 1 Investment Limited Partnership, Fuji Film Co., Ltd., and CellSource Co., Ltd.: conducted third-party allotment of shares to other investorsSources

Fujio Yoshioka, Specially Appointed Professor (Department of Health Sciences, Graduate School of Medicine, Osaka University, Future Medical Science Course), was appointed as CTO (Chief Technology Officer)Sources

Commercial cell culture processing facility (commonly known as "CLiC-1") has obtained "Specific Cell Processing Manufacturing License" (Facility Number: FA5210001)Sources

Agreed to a contract with VC Cell Therapy Inc. regarding clinical trial regenerative medicine products manufacturing and quality controlSources

Contract concluded with Canon Cure Inc. for technical support and related mattersSources

Concluded a joint research agreement with Asahi Intecc Inc. for the development of new regenerative medicine treatment technologiesSources

The doctor-led clinical trial (Cohort B) has started, and transplantation surgery was performed at Juntendo University School of Medicine Juntendo Hospital (first case transplantation)Sources

CellSource Inc. adopted our contract manufacturing service for specific cell processing productsSources

End of doctor-led clinical trial (Cohort B) (completion of 5th transplantation)Sources

Listed on the Tokyo Stock Exchange Growth MarketSources

Decided to move into Silicon Valley business base (established by the Ministry of Economy, Trade and Industry)Sources

Established Quolips Healthcare Science Inc. in Chuo Ward, Tokyo, to conduct culture supernatant businessSources

Signed a joint research and development agreement with Daiichi Sankyo Co., Ltd. to obtain manufacturing and sales approval for human iPS cell-derived cardiac muscle cell sheets (ended in March 2026)Sources

§07

News

22 ARTICLES

NHK Program "iPS Cell Special" Broadcast AnnouncementSources

The program "Intellectual Frontier: Tamori & Shinya Yamanaka's!? iPS Cell Special" that our company interviewed is scheduled to air on NHK (nationwide) at 7:30 p.m. on November 7, 2026.

First Heart transplant press conference covered by mediaSources

The first transplant of the regenerative medicine product 'Heart' was performed, and the surgeon and patient held a press conference. The conference was reported by multiple media outlets including NHK, Sankei, Kyodo, Yomiuri TV, Yomiuri Shimbun, Asahi Shimbun, and Nikkei. The patient reported good postoperative progress and was able to take deep breaths.

NHK Broadcast Schedule: New Project X – The ChallengersSources

The NHK program 'New Project X – The Challengers', which was interviewed by Qualips Inc., will be broadcast on October 31, 2026 at 20:07. The program focuses on research on iPS cells. Please watch it.

ReHeart Second Transplant Press Conference ReportedSources

The press conference regarding the second transplant of the regenerative medicine product "ReHeart" was covered by the media. NHK reported the first iPS cardiomyocyte sheet transplant surgery in Kyushu after insurance coverage, and the Yomiuri Shimbun introduced the surgery using iPS cells at Kyushu University Hospital.

First Transplant of Cuorips’ Regenerative Medicine Product Rehert Covered by MediaSources

Cuorips Co., Ltd. performed the first transplant of Rehert, a regenerative medicine product, and the procedure was covered by multiple media outlets. Surgery using an iPS cell-derived cardiac muscle sheet was performed at a hospital in Osaka and has drawn attention as the world’s first practical application. Comments from the Chief Medical Science Officer were also published.

Interview Article Published on Qualips' Facility at Nakanoshima QrossSources

Qualips, Inc. established a new facility at Nakanoshima Qross in Osaka and began trials aimed at mass-producing regenerative medicine cells. An interview article has been published introducing the company's initiative.

iPS Heart Muscle Sheet to Be Displayed at Expo Legacy EventSources

An iPS heart muscle sheet attracted attention when it was displayed at the Osaka Healthcare Pavilion during the memorial event 1st Anniversary EXPO 2025 for Expo 2025 Osaka, Kansai. The event is scheduled for October 11–12, 2026.

Qualips CEO Discusses 20 Years of iPS Cell ResearchSources

Sankei News published an interview with Qualips CEO Takayuki Kusanagi. He discusses drug pricing and the outlook for cardiac muscle sheets to become a standard treatment.

Sankei News Publishes Interview with Chief Medical Science Officer on 20 Years of iPS CellsSources

Sankei News published an interview on August 17, 2026, marking 20 years of iPS cell research. Chief Medical Science Officer Sawada discussed progress in regenerative medicine and new treatment options for severe heart failure.

iPS Cardiac Muscle Sheet Featured at Resona EXPO Re:FutureSources

An iPS-cell-derived cardiac muscle sheet will be exhibited at Resona EXPO Re:Future from August 21 to 23, 2026. The sheet attracted attention at the Pasona pavilion during Expo 2025 Osaka, Kansai.

§08

Public records

GOV
National Tax Agency basic information7020001120540
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
クオリプス株式会社
Trade name (kana)
クオリプス
Name in English
Corporation type
301
Address
〒103-0023 東京都中央区日本橋本町3丁目11番5号日本橋ライフサイエンスビルディング2、507
Postal code
1030023
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2017-03-27
Update date
2018-07-09
Change date
2018-07-02
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2306342
METI gBizINFO7020001120540
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
7020001120540
Trade name
クオリプス株式会社
Trade name (kana)
クオリプス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府大阪市北区中之島4丁目3番51号NakanoshimaQross8F、O-Nexus内
Postal code
5300005
Prefecture
大阪府
Prefecture code
27
City or district
大阪市北区
City code
127
Street address
中之島4丁目3番51号NakanoshimaQross8F、O-Nexus内
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長  草薙 尊之
Capital
1769678000
Employees
51
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2026-09-07
Key information
7020001120540
§09

Sources & updates

SOURCES
↑